Page last updated: 2024-08-23

amikacin and Cystic Fibrosis of Pancreas

amikacin has been researched along with Cystic Fibrosis of Pancreas in 98 studies

Research

Studies (98)

Timeframe	Studies, this research(%)	All Research%
pre-1990	15 (15.31)	18.7374
1990's	15 (15.31)	18.2507
2000's	20 (20.41)	29.6817
2010's	37 (37.76)	24.3611
2020's	11 (11.22)	2.80

Authors

Authors	Studies
Alba, L; Chen, Y; Garber, E; Saiman, L; Tabibi, S; Zhou, J	1
Attrée, I; Ducruix, A; El Garch, F; Llanes, C; Muller, C; Phan, G; Plésiat, P; Vettoretti, L	1
Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O	1
Beceiro, A; Bou, G; Doumith, M; Livermore, DM; Tomás, M; Turton, JF; Warner, M; Woodford, N	1
Ciciriello, F; Cirillo, DM; D'Andrea, MM; De Santis, F; Fraziano, M; Henrici De Angelis, L; Lorè, NI; Lucidi, V; Olimpieri, T; Poerio, N; Riva, C; Rossi, M	1
Güler, N; Süleyman, A; Tamay, Z	1
Coria-Jiménez, VR; Cuevas-Schacht, F; Gerónimo-Gallegos, A; Gutiérrez-Santana, JC; López-López, M; Martínez-Corona, MB; Toscano-Garibay, JD	1
Baniasadi, S; Hassanzad, M; Kouhestani, F	1
Brown-Elliott, BA; Brunton, AE; Fuss, C; Griffith, DE; Philley, JV; Siegel, SAR; Strnad, L; Sullivan, PE; Wallace, RJ; Winthrop, KL	1
Beigverdi, R; Emaneini, M; Halimi, S; Jabalameli, F; Siroosi, M	1
Bilton, D; Cipolli, M; Clancy, JP; Eagle, G; Fajac, I; Galeva, I; Gupta, R; Konstan, MW; Liu, K; McGinnis, JP; Minic, P; Pressler, T; Quittner, AL; Sands, D; Solé, A	1
Marsot, A; Matouk, E; Pasche, V; Thirion, DJG	1
Bouchet, S; Bui, S; Fayon, M; Marquet, P; Monchaud, C; Woillard, JB	1
Bell, SC; Bordin, A; Clark, JE; Coulter, C; Hackett, H; Jennison, AV; Nimmo, GR; Pandey, S; Pardo, C; Syrmis, M; Wainwright, CE; Whiley, DM	1
Bilton, D; Ciesielska, M; Cipolli, M; Clancy, JP; Fajac, I; Galeva, I; Jumadilova, Z; Konstan, MW; Minic, P; Pressler, T; Quittner, AL; Sands, D; Solé, A	1
Bernkop-Schnürch, A; Ellemunter, H; Fontana, S; Griesser, J; Gutierrez, AM; Hetényi, G; Niedermayr, K; Szabó, P	1
Da Dalt, L; Guarnieri, M; Lucca, F; Muffato, G; Rigoli, R; Ros, M	1
Guimbellot, JS; Poore, TS; Virella-Lowell, I	1
Bhakta, ZN; Carveth, H; Huynh, HQ; Illamola, SM; Liou, TG; Liu, X; Sherwin, CM; Young, DC	1
Charbek, E; Rowbotham, NJ; Smith, S	1
Arora, V; Autry, EB; Burgess, DR; Burgess, DS; Kuhn, RJ; Nolt, VD; Pijut, KD; Williams, WC	1
Griffith, DE	1
Marsot, A; Pasche, V; Thirion, DJG	1
Billings, J; Burns, JL; Clancy, JP; Dupont, L; Fustik, S; Goss, CH; Govan, JR; Gupta, R; Konstan, MW; Lymp, J; Minic, P; Quittner, AL; Ramsey, B; Rubenstein, RC; Saiman, L; Young, KR	1
Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT	1
Antoniu, S; Azoicai, D	1
Bhattacharyya, D; Brewer, CC; Fleshner, M; Folio, LR; Glaser, TS; Holland, SM; Olivier, KN; Park, IK; Prevots, DR; Sampaio, EP; Shallom, S; Shaw, PA; Siegelman, JR; Zalewski, CK; Zelazny, AM	1
Clancy, JP; Ehsan, Z; Wetzel, JD	1
Goss, CH; Quon, BS; Ramsey, BW	1
Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Gupta, R; Hammel, JP; Okusanya, OO	1
Aghazadeh, M; Hojabri, T; Hojabri, Z; Mahdian, R; Nahaei, MR; Pajand, O; Pirzadeh, T; Rahmati, M	1
Prescott, WA	1
Fiel, SB	1
Ratjen, F; Waters, V	1
Balducci, AG; Belotti, S; Bettini, R; Buttini, F; Colombo, G; Colombo, P; Politis, S; Rekkas, D; Rossi, A	2
Benwill, JL; Wallace, RJ	1
Beaudoin, T; LiPuma, JJ; Tom, SK; Waters, V; Yau, YC	1
Clancy, JP; Ehsan, Z	1
Cullina, J; Hauser, AR; Jain, M; McColley, SA; Potter, E; Powers, C; Prickett, MH	1
Abdel-Haq, N; Ang, JY; Nicolau, DP; Satlin, MJ; Thabit, AK; van Duin, D; Zhu, F	1
Carroll, K; Cohen, DM; Cross, CP; Feeney, MP; Garinis, AC; Gold, JA; Hunter, LL; Keefe, DH; Putterman, DB; Srikanth, P; Steyger, PS	1
Bilton, D	1
Halacova, M; Kotaska, K; Kukacka, J; Kuzelova, M; Prusa, R; Ticha, J; Vavrova, V	1
Ambrose, PG; Bhavnani, SM; Dupont, LJ; Forrest, A; Gupta, R; Hammel, J; Mackinson, C; Minic, P; Mulder, GJ; Okusanya, OO	1
Brody, SL; Cannon, CL; Hogue, LA; LiPuma, JJ; Taylor, JB; Walter, MJ	1
Becker, CG; Becker, HM; Camargos, PA; Guimarães, RE; Martins, LM	1
Ali-Dinar, T; Colin, AA	1
Appelbaum, PC; Beachel, L; Clark, C; Credito, K; Kosowska-Shick, K; McGhee, P; Pankuch, GA	1
Cofta, S; Lisowska, A; Oracz, G; Pogorzelski, A; Skorupa, W; Socha, J; Szydłowski, J; Walkowiak, J	1
Bozkurt-Güzel, C; Gerçeker, AA	1
Hewer, SL	1
Jahnke, N; Remmington, T; Ryan, G	1
Adriensen, B; Husson, MO; Loiez, C; Massoni-Cristante, S	1
Forslöw, U; Geborek, A; Heurlin, N; Hjelte, L; Petrini, B	1
Halacová, M; Kotaska, K; Průsa, R; Vávrová, V	1
Perederko, LV; Polikarpova, SV; Postnikov, SS; Semykin, SIu	1
Islam, S; Jalal, S; Wretlind, B	1
de Britto, MC; Magalhães, M; Vandamme, P	1
Alvarez, A; Baquero, F; Cantón, R; Cobos, N; de Gracia, J; García-Quetglas, E; Gartner, S; Honorato, J; Oliver, A; Salcedo, A	1
Bedwell, DM; Du, M; Fan, L; Keeling, KM; Kovaçs, T; Liu, X; Sorscher, E	1
Petrini, B	1
Bossuyt, X; Godding, V; Leal, T; Lebecque, P; Reychler, G; Zylberberg, K	1
Dubovik, LG; Perederko, LV; Polikarpova, SV; Postnikov, SS; Semykin, SIu	1
Gilly, R; Grenier, B	1
Aronoff, SC; Klinger, JD	1
Marks, MI; Scribner, RK; Tarpay, MM; Weber, AH; Welch, DF	1
Baran, D; Klastersky, J; Levy, J	1
Kitade, M; Moritaka, T; Nakanishi, N; Ueda, N	1
Ategbo, S; Canis, F; Courcol, R; Husson, MO; Leclerc, H; Turck, D; Vic, P	1
Hurley, JC; Miller, GH; Smith, AL	1
Arrouet-Lagandre, C; Ategbo, S; Deschildre, A; Druon, D; Elian, JC; Farriaux, JP; Husson, MO; Loeuille, GA; Tassin, E; Turck, D; Vic, P	1
Hampel, B; Kraemer, R; Ruedeberg, A; Schaad, UB; Wedgwood, J	1
Ategbo, S; Canis, F; Courcol, RJ; Husson, MO; Launay, V; Turck, D; Vic, P; Vincent, A	1
Ategbo, S; Druon, D; Elian, JC; Farriaux, JP; Gottrand, F; Launay, V; Loeuille, GA; Turck, D; Vic, P	1
Beringer, PM; Jelliffe, RW; Vinks, AA	1
Diot, P	1
Aebischer, CC; Bettinelli, A; Bianchetti, MG; Truttmann, AC; von Vigier, RO; Wermuth, B; Zindler-Schmocker, K	1
Colin, AA	1
Baran, D; Byl, B; Herschuelz, A; Jacobs, F; Thys, JP	1
Delatour, F; Faurisson, F; Jelazko, P	1
Hoogkamp-Korstanje, JA; Westerdaal, NA	1
Dooley, RR; Lau, WK; Osher, AB; Young, LS	1
Finkelstein, E; Hall, K	1
Kowarski, A; Lietman, PS; Vogelstein, B	1
Artho, G; Bianchetti, MG; Hügli, R; Peheim, E; Schaad, UB; Wiesmann, UN	1
Bataillon, V; Lafitte, JJ; Lhermitte, M; Pommery, J; Roussel, P	1
Autret, E; Grenier, B; Lorette, G; Marchand, S; Vaillant, L	1
Ansorg, R; Müller, KD; Wiora, J	1
Agueda, L; Bertrou, A; Chabanon, G; Henry, S; Marty, N	1
Bakhache, P; Chivet, C; Douchain, F; Houdas, S; Lebas, L; Pautard, JC	1
Buehlmann, U; Guenin, K; Kraemer, R; Schaad, UB; Wedgwood-Krucko, J	1
Kraemer, R; Schaad, UB; Suter, S; Wedgwood-Krucko, J	1
Delage, G; Desautels, L; Lamarre, A; Lapierre, JG; Lasalle, R; Legault, S; Masson, P; Spier, S	1
Katosova, LK; Nekhorosheva, AG; Skala, LZ; Sotnikova, GD; Volkov, IK	1
Chadwick, EG; Shulman, ST; Yogev, R	1
Autret, E; Breteau, M; Grenier, B; Marchand, S	1
Grassi, C	1

Reviews

15 review(s) available for amikacin and Cystic Fibrosis of Pancreas

Article	Year
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. The Cochrane database of systematic reviews, 2018, 10-30, Volume: 10 Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Cystic Fibrosis; Disease Progression; Forced Expiratory Volume; Humans; Injections, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Ticarcillin; Tobramycin	2018
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatric pulmonology, 2013, Volume: 48, Issue:11 Topics: Adult; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Child; Cystic Fibrosis; Disease Progression; Gentamicins; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2013
Novel amikacin inhaled formulation for the treatment of lower respiratory tract infections. Drugs of today (Barcelona, Spain : 1998), 2013, Volume: 49, Issue:11 Topics: Administration, Inhalation; Amikacin; Animals; Anti-Bacterial Agents; Bacteria; Cystic Fibrosis; Humans; Liposomes; Pneumonia, Ventilator-Associated; Respiratory Tract Infections	2013
Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients. Expert opinion on investigational drugs, 2014, Volume: 23, Issue:5 Topics: Administration, Inhalation; Amikacin; Animals; Cystic Fibrosis; Humans; Liposomes; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome	2014
Inhaled antibiotics for lower airway infections. Annals of the American Thoracic Society, 2014, Volume: 11, Issue:3 Topics: Administration, Inhalation; Amikacin; Amphotericin B; Anti-Bacterial Agents; Aztreonam; Ceftazidime; Colistin; Cystic Fibrosis; Gentamicins; Humans; Nebulizers and Vaporizers; Respiratory Tract Infections; Tobramycin	2014
Aerosolized antibiotics in cystic fibrosis: an update. Expert review of respiratory medicine, 2014, Volume: 8, Issue:3 Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Aztreonam; Colistin; Cystic Fibrosis; Equipment Design; Humans; Levofloxacin; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin	2014
Inhaled liposomal amikacin. Expert review of respiratory medicine, 2014, Volume: 8, Issue:4 Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Treatment Outcome	2014
Mycobacterium abscessus: challenges in diagnosis and treatment. Current opinion in infectious diseases, 2014, Volume: 27, Issue:6 Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Antibiotics, Antitubercular; Azithromycin; Cystic Fibrosis; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Genotype; Humans; Molecular Diagnostic Techniques; Molecular Sequence Data; Mycobacterium Infections, Nontuberculous; Polymorphism, Single Nucleotide; Respiratory Tract Infections; Sequence Analysis, DNA; Transcription Factors; Treatment Outcome	2014
Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future microbiology, 2015, Volume: 10, Issue:12 Topics: Administration, Inhalation; Aerosols; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Drug Carriers; Humans; Liposomes; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections	2015
Inhaled antibiotics in cystic fibrosis: what's new? Journal of the Royal Society of Medicine, 2012, Volume: 105 Suppl 2 Topics: Administration, Inhalation; Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Child; Child, Preschool; Ciprofloxacin; Clinical Trials, Phase III as Topic; Cystic Fibrosis; Female; Follow-Up Studies; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Incidence; Infant; Male; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Survival Rate; Tobramycin; Treatment Outcome	2012
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. The Cochrane database of systematic reviews, 2012, Dec-12, Volume: 12 Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Cystic Fibrosis; Disease Progression; Humans; Injections, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Ticarcillin; Tobramycin	2012
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2005, Volume: 11, Issue:9 Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchopneumonia; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Inhalation; Injections, Intravenous; Lung Diseases; Pneumonia, Bacterial; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2005
Mycobacterium abscessus: an emerging rapid-growing potential pathogen. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2006, Volume: 114, Issue:5 Topics: Administration, Oral; Amikacin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Minocycline; Mycobacterium; Mycobacterium Infections; Respiratory Tract Infections; Skin; Soft Tissue Infections; Species Specificity; Surgical Wound Infection; Tigecycline; Tuberculosis, Cutaneous; Wounds and Injuries	2006
Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. The Journal of antimicrobial chemotherapy, 1998, Volume: 41, Issue:1 Topics: Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Drug Administration Schedule; Humans	1998
Respiratory infections: clinical evaluation. Clinical therapeutics, 1985, Volume: 7 Suppl A Topics: Amikacin; Carbenicillin; Cefotaxime; Cystic Fibrosis; Drug Therapy, Combination; Enterobacteriaceae; Haemophilus influenzae; Humans; Piperacillin; Pseudomonas Infections; Respiratory Tract Infections; Streptococcus; Streptococcus pneumoniae; Tobramycin	1985

Trials

15 trial(s) available for amikacin and Cystic Fibrosis of Pancreas

Article	Year
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2020, Volume: 19, Issue:2 Topics: Administration, Inhalation; Adult; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Female; Hospitalization; Humans; Liposomes; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Sputum; Surveys and Questionnaires; Symptom Assessment; Symptom Flare Up; Tobramycin; Treatment Outcome	2020
Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021, Volume: 20, Issue:6 Topics: Administration, Inhalation; Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Child; Chronic Disease; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Liposomes; Male; Middle Aged; Pseudomonas Infections; Suspensions	2021
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax, 2013, Volume: 68, Issue:9 Topics: Adolescent; Adult; Amikacin; Analysis of Variance; Anti-Bacterial Agents; Child; Cystic Fibrosis; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Liposomes; Male; Microbial Sensitivity Tests; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Quality of Life; Sputum; Young Adult	2013
Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin. Journal of clinical pharmacy and therapeutics, 2008, Volume: 33, Issue:4 Topics: Acetylglucosaminidase; Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Biomarkers; Child; Child, Preschool; Creatinine; Cystatin C; Cystatins; Cystic Fibrosis; Drug Monitoring; Female; Glomerular Filtration Rate; Humans; Infusions, Intravenous; Kidney; Male; ROC Curve; Time Factors	2008
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9 Topics: Administration, Inhalation; Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Liposomes; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Young Adult	2009
Antibiotic therapy and fat digestion and absorption in cystic fibrosis. Acta biochimica Polonica, 2011, Volume: 58, Issue:3 Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Breath Tests; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Digestion; Exocrine Pancreatic Insufficiency; Fats; Female; Humans; Intestinal Absorption; Lipid Metabolism; Male; Young Adult	2011
[Efficacy and safety of cefoperazone/sulbactam in the treatment of children with mucoviscidosis during exacerbation of the bronchopulmonary process]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2003, Volume: 48, Issue:12 Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Cefoperazone; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Pneumonia, Bacterial; Pneumonia, Staphylococcal; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Sulbactam; Treatment Outcome	2003
[Clinical and bacteriological efficacy and tolerability of meropenem in the treatment of bronchopulmonary affections in children with mucoviscidosis]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2006, Volume: 51, Issue:7 Topics: Amikacin; Anti-Bacterial Agents; Bronchopneumonia; Child; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Thienamycins; Treatment Outcome	2006
Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis. The Journal of antimicrobial chemotherapy, 1982, Volume: 10, Issue:3 Topics: Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Kanamycin; Kinetics; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	1982
Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. European journal of pediatrics, 1996, Volume: 155, Issue:11 Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Audiometry; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Female; Humans; Infant; Kidney Function Tests; Male; Pneumonia, Bacterial; Pseudomonas Infections	1996
Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. The Pediatric infectious disease journal, 1997, Volume: 16, Issue:1 Topics: Adolescent; Adult; Amikacin; Anti-Infective Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Male; Pseudomonas Infections; Treatment Outcome	1997
Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis. Archives of disease in childhood, 1997, Volume: 76, Issue:5 Topics: Adolescent; Adult; Amikacin; Anthropometry; Body Composition; Ceftazidime; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Nutritional Status; Opportunistic Infections; Prospective Studies; Pseudomonas Infections; Tobramycin	1997
A simple tool for monitoring nebulized amikacin treatments based on a single urine assay. Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine, 2001,Spring, Volume: 14, Issue:1 Topics: Administration, Inhalation; Adult; Amikacin; Creatinine; Cystic Fibrosis; Drug Monitoring; Female; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pneumonia, Bacterial; Pseudomonas Infections; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome	2001
Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1989, Volume: 8, Issue:10 Topics: Adolescent; Adult; Amikacin; Aztreonam; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Pseudomonas Infections; Randomized Controlled Trials as Topic	1989
Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. The Journal of pediatrics, 1987, Volume: 111, Issue:4 Topics: Acute Disease; Administration, Inhalation; Adolescent; Adult; Airway Resistance; Amikacin; Ceftazidime; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Humans; Oxygen Consumption; Pseudomonas Infections; Respiratory Tract Infections; Vital Capacity	1987

Other Studies

68 other study(ies) available for amikacin and Cystic Fibrosis of Pancreas

Article	Year
Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3 Topics: Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests	2007
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5 Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactams; Cystic Fibrosis; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum	2009
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Aerosols; Anti-Bacterial Agents; Bacteria; Biofilms; Chronic Disease; Ciprofloxacin; Colony Count, Microbial; Cystic Fibrosis; Humans; Levofloxacin; Lung Diseases; Microbial Sensitivity Tests; Ofloxacin; Sputum	2010
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Resistance, Multiple; Electrophoresis, Gel, Pulsed-Field; Humans; Membrane Transport Proteins; Mutation; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation	2010
Combined Host- and Pathogen-Directed Therapy for the Control of Mycobacterium abscessus Infection. Microbiology spectrum, 2022, 02-23, Volume: 10, Issue:1 Topics: Amikacin; Animals; Anti-Bacterial Agents; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Liposomes; Macrophages; Male; Mice; Mice, Inbred C57BL; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Phagosomes; Phosphatidylinositol Phosphates; Reactive Oxygen Species	2022
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study. Pediatric pulmonology, 2022, Volume: 57, Issue:11 Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Humans; Levofloxacin; Meropenem; Piperacillin; Retrospective Studies; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination	2022
High Rates of Extensively Drug-Resistant Pseudomonas aeruginosa in Children with Cystic Fibrosis. Current microbiology, 2022, Oct-08, Volume: 79, Issue:11 Topics: Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Child; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Random Amplified Polymorphic DNA Technique; Reinfection	2022
Comparing the Efficacy and Safety of Nebulized Gentamicin Plus Amikacin Current drug safety, 2024, Volume: 19, Issue:1 Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Cross-Sectional Studies; Cystic Fibrosis; Gentamicins; Humans; Pseudomonas Infections; Tobramycin	2024
Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. Chest, 2023, Volume: 164, Issue:4 Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Clofazimine; Cystic Fibrosis; Drug Resistance, Bacterial; Female; Humans; Leprostatic Agents; Liposomes; Macrolides; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous	2023
Determining effects of nitrate, arginine, and ferrous on antibiotic recalcitrance of clinical strains of Pseudomonas aeruginosa in biofilm-inspired alginate encapsulates. Annals of clinical microbiology and antimicrobials, 2023, Jul-20, Volume: 22, Issue:1 Topics: Alginates; Amikacin; Anti-Bacterial Agents; Arginine; Biofilms; Ciprofloxacin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Nitrates; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2023
Amikacin nomogram for treatment of adult cystic fibrosis exacerbations based on an external evaluation of a population pharmacokinetic model. Pediatric pulmonology, 2020, Volume: 55, Issue:5 Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Male; Middle Aged; Models, Biological; Nomograms; Symptom Flare Up; Young Adult	2020
A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis. Therapeutic drug monitoring, 2021, 08-01, Volume: 43, Issue:4 Topics: Administration, Intravenous; Amikacin; Anti-Bacterial Agents; Child; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Monte Carlo Method	2021
Rapid macrolide and amikacin resistance testing for Journal of medical microbiology, 2021, Volume: 70, Issue:4 Topics: Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Drug Resistance, Bacterial; Environmental Microbiology; Humans; Macrolides; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Respiratory System	2021
Amikacin-containing self-emulsifying delivery systems via pulmonary administration for treatment of bacterial infections of cystic fibrosis patients. Nanomedicine (London, England), 2018, 04-01, Volume: 13, Issue:7 Topics: Amikacin; Bacterial Infections; Cystic Fibrosis; Drug Delivery Systems; Drug Liberation; Emulsions; Humans; Hydrophobic and Hydrophilic Interactions; Lipids; Mucus; Permeability; Pseudomonas aeruginosa; Respiratory Therapy	2018
Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013). The clinical respiratory journal, 2018, Volume: 12, Issue:7 Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Levofloxacin; Longitudinal Studies; Male; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult	2018
Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis. Pediatric pulmonology, 2018, Volume: 53, Issue:7 Topics: Amikacin; Anti-Bacterial Agents; Child; Ciprofloxacin; Clindamycin; Cystic Fibrosis; Gram-Negative Bacterial Infections; Humans; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Rhodospirillaceae; Stenotrophomonas maltophilia; Virulence	2018
Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:10 Topics: Adolescent; Adult; Amikacin; Aminoglycosides; Creatinine; Cystic Fibrosis; Female; Humans; Male; Middle Aged; Retrospective Studies; Young Adult	2018
Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation. Pediatric pulmonology, 2019, Volume: 54, Issue:1 Topics: Adult; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Lung; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Pseudomonas aeruginosa; Retrospective Studies; Young Adult	2019
Mycobacterium abscessus and Antibiotic Resistance: Same As It Ever Was. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 10-30, Volume: 69, Issue:10 Topics: Amikacin; Anti-Bacterial Agents; Child; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Mycobacterium abscessus	2019
What is the recommended amikacin dosing for cystic fibrosis patients with acute pulmonary exacerbations? Pediatric pulmonology, 2019, Volume: 54, Issue:11 Topics: Adult; Amikacin; Aminoglycosides; Cystic Fibrosis; Humans; Monte Carlo Method; Tobramycin	2019
Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Annals of the American Thoracic Society, 2014, Volume: 11, Issue:1 Topics: Administration, Inhalation; Adult; Aged; Amikacin; Anti-Bacterial Agents; Bronchiectasis; Cystic Fibrosis; Female; Humans; Kartagener Syndrome; Male; Middle Aged; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Retrospective Studies; Sputum; Treatment Outcome; Tuberculosis, Pulmonary	2014
Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:9 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Area Under Curve; Child; Clinical Trials, Phase II as Topic; Cystic Fibrosis; Female; Humans; Liposomes; Lung; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Function Tests; Young Adult	2014
Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2014, Volume: 24 Topics: Amikacin; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Burns; Cephalosporinase; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Escherichia coli Proteins; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2014
A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Respiratory care, 2014, Volume: 59, Issue:9 Topics: Adult; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Cystic Fibrosis; Disease Progression; Drug Administration Schedule; Drug Monitoring; Gentamicins; Health Care Surveys; Humans; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tobramycin; United States	2014
Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction. International journal of pharmaceutics, 2014, Aug-25, Volume: 471, Issue:1-2 Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Drug Carriers; Drug Compounding; Drug Design; Excipients; Humans; Particle Size; Powders; Surface Properties; Thermogravimetry	2014
Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015, Volume: 93 Topics: Administration, Inhalation; Aerosols; Amikacin; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Cystic Fibrosis; Desiccation; Ethanol; Humans; Motion; Particle Size; Powders; Respiratory Tract Infections; Rheology; Solubility; Surface Properties; Technology, Pharmaceutical; Temperature	2015
Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Achromobacter; Amikacin; Anti-Bacterial Agents; Aztreonam; Biofilms; Colistin; Cystic Fibrosis; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Plankton; Tobramycin	2016
Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene. Thorax, 2017, Volume: 72, Issue:1 Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Antiporters; Bacterial Proteins; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Drug Resistance, Bacterial; Female; Gene Expression; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; RNA, Messenger; Time Factors; Young Adult	2017
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:10 Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2016
The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017, Volume: 16, Issue:3 Topics: Adolescent; Adult; Age Factors; Amikacin; Anti-Bacterial Agents; Audiometry, Pure-Tone; Bacterial Infections; Cystic Fibrosis; Female; Hearing Loss; Humans; Male; Middle Aged; Patient Outcome Assessment; Sex Factors; Time; Tobramycin; United States; Vancomycin	2017
What did we learn from the North American Cystic Fibrosis Conference? Journal of the Royal Society of Medicine, 2008, Volume: 101 Suppl 1 Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Chloride Channels; Clinical Trials as Topic; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Diuretics, Osmotic; Genetic Therapy; Humans; Ion Transport; Mannitol; Quality of Health Care; Saline Solution, Hypertonic; United States	2008
Entry of Burkholderia organisms into respiratory epithelium: CFTR, microfilament and microtubule dependence. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2010, Volume: 9, Issue:1 Topics: Actin Cytoskeleton; Amikacin; Anti-Bacterial Agents; Burkholderia gladioli; Burkholderia Infections; Ceftazidime; Cell Line, Transformed; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Therapy, Combination; Epithelial Cells; Humans; Meropenem; Microbial Sensitivity Tests; Microscopy, Electron, Transmission; Microtubules; Respiratory Mucosa; Thienamycins; Virulence	2010
Hearing loss in cystic fibrosis. International journal of pediatric otorhinolaryngology, 2010, Volume: 74, Issue:5 Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Audiometry, Pure-Tone; Child; Child, Preschool; Cystic Fibrosis; Female; Gentamicins; Hearing Loss, Sensorineural; Humans; Infant; Male; Otoacoustic Emissions, Spontaneous	2010
Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up. Pediatric pulmonology, 2010, Volume: 45, Issue:6 Topics: Administration, Oral; Adult; Amikacin; Anti-Bacterial Agents; Clarithromycin; Cystic Fibrosis; Drug Therapy, Combination; Female; Forced Expiratory Volume; Gram-Negative Bacterial Infections; Humans; Mycobacterium; Mycobacterium Infections; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Stenotrophomonas maltophilia	2010
In vitro activity of fusidic acid (CEM-102, sodium fusidate) against Staphylococcus aureus isolates from cystic fibrosis patients and its effect on the activities of tobramycin and amikacin against Pseudomonas aeruginosa and Burkholderia cepacia. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:5 Topics: Amikacin; Burkholderia cepacia; Cystic Fibrosis; Drug Synergism; Fusidic Acid; Humans; Pseudomonas aeruginosa; Staphylococcus aureus; Tobramycin	2011
Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. The Journal of antibiotics, 2012, Volume: 65, Issue:2 Topics: Amikacin; Anti-Bacterial Agents; Bacterial Load; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections	2012
[Evaluation of a E-test method to detect bactericidy of beta lactam-aminoglycoside associations against Pseudomonas aeruginosa isolates from cystic fibrosis]. Pathologie-biologie, 2003, Volume: 51, Issue:3 Topics: Amikacin; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin	2003
Early chemotherapy for non-tuberculous mycobacterial infections in patients with cystic fibrosis. Acta paediatrica (Oslo, Norway : 1992), 2003, Volume: 92, Issue:8 Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Child; Clarithromycin; Cohort Studies; Cystic Fibrosis; Ethambutol; Female; Humans; Male; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium Infections, Nontuberculous; Mycobacterium kansasii; Retrospective Studies; Rifampin; Streptomycin	2003
[Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis]. Casopis lekaru ceskych, 2004, Volume: 143, Issue:3 Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Child; Computer Simulation; Cystic Fibrosis; Drug Administration Schedule; Female; Humans; Male; Models, Biological; Pseudomonas Infections; Respiratory Tract Infections	2004
Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2004, Volume: 10, Issue:10 Topics: Amikacin; Anti-Bacterial Agents; Bacterial Proteins; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sequence Analysis, DNA	2004
Burkholderia cepacia genomovar III and Burkholderia vietnamiensis double infection in a cystic fibrosis child. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2002, Volume: 1, Issue:4 Topics: Amikacin; Anti-Infective Agents; Burkholderia; Burkholderia cepacia complex; Burkholderia Infections; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Infant; Male; Respiratory Tract Infections; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination	2002
Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. Journal of molecular medicine (Berlin, Germany), 2006, Volume: 84, Issue:7 Topics: Amikacin; Amino Acid Sequence; Animals; Base Sequence; Codon, Nonsense; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Gene Expression Regulation; Gentamicins; Humans; Intestinal Mucosa; Intestines; Mice; Mice, Transgenic; Molecular Sequence Data; Protein Biosynthesis	2006
Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2006, Volume: 5, Issue:4 Topics: Administration, Inhalation; Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Child; Chronic Disease; Cystic Fibrosis; Female; Humans; Male; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin	2006
[Azlocillin treatment of Pseudomonas aeruginosa bronchopulmonary infections in children with cystic fibrosis]. Presse medicale (Paris, France : 1983), 1984, Mar-29, Volume: 13, Issue:13 Topics: Adolescent; Amikacin; Azlocillin; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Sputum	1984
In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis. Antimicrobial agents and chemotherapy, 1984, Volume: 25, Issue:2 Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Child; Cystic Fibrosis; Drug Therapy, Combination; Humans; Kanamycin; Penicillin Resistance; Piperacillin; Pseudomonas Infections; Ticarcillin	1984
Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrobial agents and chemotherapy, 1982, Volume: 21, Issue:6 Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Cystic Fibrosis; Gentamicins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tobramycin	1982
[A case of cystic fibrosis in a Japanese student]. Nihon Kyobu Shikkan Gakkai zasshi, 1995, Volume: 33, Issue:7 Topics: Administration, Inhalation; Administration, Oral; Adolescent; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cystic Fibrosis; Drug Therapy, Combination; Erythromycin; Fluoroquinolones; Humans; Japan; Male; Pseudomonas Infections; Quinolones; Respiratory Tract Infections	1995
[Bacteriological monitoring of the treatment of Pseudomonas aeruginosa infections with amikacin administrated at once-daily dosis in patients with cystic fibrosis]. Pathologie-biologie, 1995, Volume: 43, Issue:4 Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Electrophoresis, Gel, Pulsed-Field; Humans; Infusions, Intravenous; Monitoring, Physiologic; Pseudomonas aeruginosa; Pseudomonas Infections	1995
Mechanism of amikacin resistance in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Diagnostic microbiology and infectious disease, 1995, Volume: 22, Issue:4 Topics: Amikacin; Anti-Bacterial Agents; Culture Media; Cystic Fibrosis; DNA Probes; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa	1995
Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients. The Journal of antimicrobial chemotherapy, 1997, Volume: 39, Issue:3 Topics: Adolescent; Adult; Amikacin; Bronchi; Child; Child, Preschool; Cystic Fibrosis; Diffusion; Female; Fluorescence Polarization Immunoassay; Half-Life; Humans; Infant; Infusions, Intravenous; Male; Sputum	1997
[Antibiotics and nebulization]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 1999, Volume: 6 Suppl 2 Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Child; Cystic Fibrosis; Humans; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections	1999
Aminoglycosides and renal magnesium homeostasis in humans. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2000, Volume: 15, Issue:6 Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Cystic Fibrosis; Drug Therapy, Combination; Electrolytes; Female; Homeostasis; Humans; Kidney; Lung Diseases; Magnesium; Male; Pseudomonas aeruginosa; Pseudomonas Infections	2000
Eradication of mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatric pulmonology, 2000, Volume: 30, Issue:3 Topics: Administration, Inhalation; Administration, Oral; Adult; Amikacin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Lung Abscess; Mycobacterium; Mycobacterium Infections; Recurrence	2000
Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. The Journal of antimicrobial chemotherapy, 2001, Volume: 48, Issue:2 Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Child; Cystic Fibrosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Sputum	2001
In vitro susceptibility of pseudomonas to four beta-lactamantibiotics (ampicillin, cephalothin, carbenicillin, piperacillin), to four aminoglycosides (kanamycin, amikacin, gentamicin, tobramycin) and to colimycin. Chemotherapy, 1979, Volume: 25, Issue:1 Topics: Amikacin; Aminoglycosides; Ampicillin; Carbenicillin; Cephalothin; Child; Colistin; Cystic Fibrosis; Gentamicins; Humans; Kanamycin; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Pseudomonas; Sputum; Tobramycin	1979
Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Pediatrics, 1977, Volume: 60, Issue:3 Topics: Acute Disease; Adolescent; Adult; Amikacin; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Kanamycin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections	1977
Aminoglycoside clearance in patients with cystic fibrosis. The Journal of pediatrics, 1979, Volume: 94, Issue:1 Topics: Amikacin; Child; Cystic Fibrosis; Humans; Kanamycin; Kidney	1979
The pharmacokinetics of amikacin in children. The Journal of pediatrics, 1977, Volume: 91, Issue:2 Topics: Adolescent; Amikacin; Anemia, Aplastic; Appendicitis; Child; Child, Preschool; Cystic Fibrosis; Female; Half-Life; Humans; Kanamycin; Kidney; Leukemia; Male; Metabolic Clearance Rate; Neoplasms; Neutropenia; Pelvic Inflammatory Disease	1977
[Assessment of the nephrotoxicity of amikacin in patients with cystic fibrosis]. Schweizerische medizinische Wochenschrift, 1992, Jun-13, Volume: 122, Issue:24 Topics: Acetylglucosaminidase; Adolescent; Adult; Albuminuria; Alpha-Globulins; Amikacin; Child; Cystic Fibrosis; Female; Humans; Kidney; Male; Protease Inhibitors	1992
The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases. The Journal of antimicrobial chemotherapy, 1992, Volume: 29, Issue:5 Topics: Amikacin; Anti-Bacterial Agents; Bronchiectasis; Bronchitis; Chronic Disease; Cystic Fibrosis; Humans; Kinetics; Macromolecular Substances; Mucus; Respiration Disorders; Sputum	1992
Suction blisters technique in amikacin diffusion through interstitial fluid in cystic fibrosis. Developmental pharmacology and therapeutics, 1991, Volume: 16, Issue:1 Topics: Amikacin; Blister; Bronchial Diseases; Child; Cystic Fibrosis; Extracellular Space; Female; Humans; Male; Suction	1991
Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Chemotherapy, 1990, Volume: 36, Issue:3 Topics: Amikacin; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tobramycin	1990
[In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis]. Pathologie-biologie, 1990, Volume: 38, Issue:5 Topics: Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; In Vitro Techniques; Lactams; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tobramycin	1990
Variability of aminoglycosides pharmacokinesis in C.F. patients in relation with certain clinical parameters. Acta Universitatis Carolinae. Medica, 1990, Volume: 36, Issue:1-4 Topics: Amikacin; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Male; Pneumonia; Pseudomonas Infections; Tobramycin	1990
Individualized aminoglycoside dosage regimens in patients with cystic fibrosis. Drug intelligence & clinical pharmacy, 1988, Volume: 22, Issue:5 Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Female; Gentamicins; Humans; Infant; Male; Spectrometry, Fluorescence; Tobramycin	1988
[Clinico-bacteriological evaluation of the effectiveness of amikacin in chronic bronchopulmonary diseases and mucoviscidosis in children]. Pediatriia, 1987, Issue:10 Topics: Adolescent; Amikacin; Bacterial Infections; Bronchiolitis; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Infant; Pneumonia	1987
Combination antibiotic therapy in pediatrics. The American journal of medicine, 1986, Jun-30, Volume: 80, Issue:6B Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Cystic Fibrosis; Drug Synergism; Drug Therapy, Combination; Humans; Immunologic Deficiency Syndromes; Infant; Infant, Newborn; Kanamycin; Lactams; Neutropenia; Peritoneal Dialysis, Continuous Ambulatory; Pseudomonas Infections; Risk	1986
Pharmacokinetics of amikacin in cystic fibrosis: a study of bronchial diffusion. European journal of clinical pharmacology, 1986, Volume: 31, Issue:1 Topics: Adolescent; Amikacin; Bronchi; Child; Child, Preschool; Cystic Fibrosis; Diffusion; Female; Half-Life; Humans; Kinetics; Male; Respiratory Tract Infections; Sputum	1986